That research was written in conjunction with the company and its what we have been waiting for with regards to strategic direction. The report gives some amazing insight.
I was unaware that EU and US trials can be merged!! 1 joint trial can be used as a pivotal study which can be used by both regulators. That sounds like a good plan and would reduce cost significantly.
Wow. Seem they are targeting the while muscular dystrophy space which adds 125,000 more potential patients on top of DMD.
Im strongly sticking with my FMG and greater than $5 call.
Excellent read.
Research report, page-4
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $90.15M | |||
| Open | High | Low | Value | Volume |
| 10.5¢ | 10.5¢ | 10.0¢ | $47.27K | 463.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 319942 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 86442 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| PER (ASX) Chart |